Skip to content

Reference information only. Therapept does not sell peptides and does not provide medical advice.Research-use notice

Therapept
Recovery & Tissue Repair43-residue N-terminally acetylated peptide

Thymosin beta-4

Thymosin beta-4 is studied as a 43-residue n-terminally acetylated peptide; the parent molecule of the tb-500 fragment in biochemical and physiological models.

UnapprovedPreclinical Models Only (Animal / Lab)Also known as: Timbetasin, Thymosin β4, Tβ4Skip to Human Evidence ↓
Other Research Areas

Thymosin beta-4 Biological Classification

Research Record

Investigated within physiological and chemical models.

At a glancePlain English, then the evidence
Not graded

What kind of compound

Peptide

43-residue N-terminally acetylated peptide.

Human testing on file

0human records

0 animal · 0 total indexed. No plain-English evidence summary on file.

Regulatory position

No FDA-approved product

Studied for

Thymosins

Reviewed 15 September 2026

Known safety concerns in this file

  • No sourced human safety summary is recorded for this compound.

Commonly compared with

No comparison set is recorded for this compound yet.

Open side-by-side comparison →
1

What is Thymosin beta-4?

Thymosin beta-4 is classified as a 43-residue n-terminally acetylated peptide; the parent molecule of the tb-500 fragment. The full-length 43-residue peptide, INN timbetasin. It is a different substance from TB-500, the seven-residue LKKTETQ fragment sold under that name, and from Ac-SDKP, its first four residues. No FDA-approved drug product exists.

2

Why are people interested in it?

Researchers and clinicians study Thymosin beta-4 primarily to understand its biological interactions, receptor binding affinity, and potential role within its biochemical class.

Primary Research Categories

  • Thymosins
  • Preclinical research compounds
3

How does it work in the body?

Thymosin beta-4 interacts with specific cellular receptors and metabolic pathways corresponding to its structural classification as a 43-residue n-terminally acetylated peptide; the parent molecule of the tb-500 fragment.

In Everyday Language: In laboratory settings, Thymosin beta-4 interacts with specific cellular targets to modulate biological signaling pathways associated with 43-residue n-terminally acetylated peptide; the parent molecule of the tb-500 fragment biology.
Cellular & Receptor Signaling: Thymosin beta-4 interacts with specific cellular receptors and metabolic pathways corresponding to its structural classification as a 43-residue n-terminally acetylated peptide; the parent molecule of the tb-500 fragment.

Biological Pathway Overview

Thymosin beta-4 Receptor & Target Interactions

This compound is evaluated in scientific research for its interactions with target cellular receptors and signaling cascades. Consult the evidence section below for specific peer-reviewed papers.

Target Pathway

Engages specific cellular signaling cascades characteristic of its structural family.

Endocrine/Paracrine Activity

Investigated for its regulatory effects on local tissue synthesis and cellular signaling.

4

What has actually been demonstrated in humans?

Preclinical Models Only (Animal / Lab)

Evidence for Thymosin beta-4 is currently derived primarily from laboratory or preclinical models. Consult the published evidence file for specific indexed studies.

Pharmaceutical Reality vs. Unregulated Research Chemicals

Thymosin beta-4 is not an FDA-approved medication. Always verify chemical identity and testing documentation before interpreting research literature.

5

What is still uncertain or unknown?

Controlled human clinical trials evaluating Thymosin beta-4 for therapeutic efficacy, safety, and pharmacokinetics are limited or absent in peer-reviewed Western registries.

Regulatory Position: Thymosin beta-4 is an investigational or unapproved compound. It is not approved by the FDA as a commercial pharmaceutical.

Companion Resources & Guides

Evidence Landscape→

Primary research publications and study designs indexed for Thymosin beta-4.

Research at a Glance

Open the full evidence file (0 records)

No evidence records in this file yet.

What Has Actually Been Studied

    What is Still Unknown

    What we know

      Editorial reading of the records below, labelled as Therapept analysis. How records are built

      What remains uncertain

        Preparation and Handling

        Lyophilized peptides ship as freeze-dried powders; whatever happens next involves diluents, concentrations and storage conditions that are compound- and product-specific.

        Preparation Resource HubWhat “lyophilized” meansConcentration calculator

        United States Regulatory Status

        No FDA-approved product

        • No approved drug product exists in Drugs@FDA.
        • FDA's compounding tables list the fragment “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500”, not the full-length peptide.
        • WADA's entry names thymosin-β4 and its derivatives together, so the parent peptide and the fragment fall under the same listing.

        WADA Anti-Doping Status

        Named at S2.3 — “Thymosin-β4 and its derivatives e.g. TB-500”, among growth factors and growth factor modulators. Prohibited at all times.

        Technical Chemical SpecificationsClick to view CAS, sequence, and molecular formulas
        Molecular weight
        4963 g/mol
        Sequence length
        46 chars
        CAS number
        77591-33-4
        PubChem CID
        16132341
        Compound class
        43-residue N-terminally acetylated peptide; the parent molecule of the TB-500 fragment
        Sequence
        Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
        Molecular formula
        C212H350N56O78S
        Molecular weight
        4963 g/mol
        CAS number
        77591-33-4
        PubChem CID
        16132341